The FY2025 (Dec) proxy of Beam Therapeutics names 16 peer companies for pay. Among Beam Therapeutics and these peers, CEO pay was 3rd highest of 5 and total shareholder return was 4th highest of 5.
3rd highest of 5in Beam Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$4.8M$14.9M
4th highest of 5in Beam Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$20$108
Pay peer group, FY2025 (Dec) proxy
| BridgeBio Pharma | ||
| CRISPR Therapeutics AG | ||
| Agios Pharmaceuticals | ||
| Denali Therapeutics | ||
| Apellis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Arcellx, Inc. | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals | Not disclosed | Not disclosed |
| Blueprint Medicines Corporation | Not disclosed | Not disclosed |
| Editas Medicine, Inc. | Not disclosed | Not disclosed |
| ImmunityBio, Inc. | Not disclosed | Not disclosed |
| Intellia Therapeutics, Inc. | Not disclosed | Not disclosed |
| Iovance Biotherapeutics, Inc. | Not disclosed | Not disclosed |
| Prime Medicine, Inc. | Not disclosed | Not disclosed |
| Rocket Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Sana Biotechnology, Inc. | Not disclosed | Not disclosed |
| Verve Therapeutics, Inc. | Not disclosed | Not disclosed |
16 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.